KemPharm, Inc. ($KMPH) - buy or sell? Stock discussion, ideas, forum

KemPharm, Inc.

KemPharm Inc.

Industry: Pharmaceuticals

Ticker	Exchange	ISIN
$KMPH	Nasdaq	US4884451075

Recent news

Synacor, Inc. reports 33.2% revenue decline in FY2020

BSQUARE Corporation reports 20.5% revenue decline in 2020 and 11.3 pp EBITDA Margin growth from -12.5% to -1.2%

eMagin Corporation CAPEX surged on 125% and Revenue jumped on 10.1%

Viveve Medical, Inc. reports 28.2% CAPEX decline in 2020 and 16.6% Revenue decline

Canadian Solar Inc. Debt jumped on 22.2% and Revenue increased on 8.6%

SMTC Corporation Debt increased on 5.4% while EBITDA decreased on 3.8%

SharpSpring, Inc. revenue growth accelerated from 21.7% in FY2019 to 29.0% in FY2020

Interlink Electronics, Inc. reports 8.1 pp EBITDA Margin growth from -2.3% to 5.9% in 2020 in 2020 while 5.7% Revenue decline

Intellicheck, Inc. Net Income jumped on 122% and Revenue jumped on 40.1%

VirnetX Holding Corp revenue jumped on 355,942% and EBITDA Margin surged on 23,179 pp from -23,127% to 52.2%

Twit about KMPH stock

Share your investment idea or question on KemPharm, Inc. stock:

Latest twits on KemPharm, Inc. (KMPH)

No twits yet. Be the first to post!

Have a question about KMPH? Ask and other investors will be eager to help you.

Have an idea about KMPH? Share it with other investors.

KemPharm, Inc. stock price chart

KemPharm, Inc. financials

mln. $	FY2019	FY2020

Revenue	12.839	13.288
EBITDA	-19.644	-5.079
Net income	-24.522	-12.760
CAPEX	0.026	0.033
Debt	79.932	70.547
Cash	3.217	4.213

About KemPharm, Inc.

KemPharm Inc. provides biopharmaceutical services. The Company offers discovery and development of therapies for the treatment of attention deficit hyperactivity disorder (ADHD), pain, and cardiovascular diseases.